In vitro and in vivo studies on the metabolism of tirofiban

Drug Metabolism and Disposition

Volumn 27, Issue 11, 1999, Pages 1360-1366

  Vickers, Stanley ^a   Theoharides, Anthony D ^a   Arison, Byron ^a   Balani, Suresh K ^a   Cui, Dan ^a   Duncan, Carol A ^a   Ellis, Joan D ^a   Gorham, Lynn M ^a   Polsky, Stacey L ^a   Prueksaritanont, Thomayant ^a   Ramjit, Harri G ^a   Slaughter, Donald E ^a   Vyas, Kamlesh P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; GLUCURONIC ACID; TIROFIBAN;

ANIMAL CELL; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DEALKYLATION; DOG; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SYNTHESIS; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME; MALE; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT;

ANIMALS; BILE; DOGS; FECES; FEMALE; FIBRINOLYTIC AGENTS; HALF-LIFE; HUMANS; MALE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; TYROSINE;

ANIMALIA; CANIS FAMILIARIS;

EID: 0032733141     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Alig L, Edenhofer A, Hadvary P, Hurzeler M, Knopp D, Muller M, Steiner B, Trzeciak A and Weller T (1992) Low molecular weight, non-peptide fibrinogen receptor antagonists. J Med Chem 35:4393-4407.
2. Anders RJ, Alexander JC, Hantsbarger GL, Burns DM, Oliver SD, Cole G and Fitzgerald DJ (1995) Demonstration of potent inhibition of platelet aggregation with an orally active GPIIb/IIIa receptor antagonist. J Am Coll Cardiol 25:117A.
3. Bednar RA, Bednar B, Gaul SL, Chang CT, Hamill T, Egbertson MS, Halczenko W, Hartman GD, Shafer JA and Gould RJ (1995) Binding of the fibrinogen receptor antagonist tirofiban to purified GPIIb/IIIa and to platelets (Abstract 256). FASEB J 9:56.
4. Brandange S and Lindblom L (1979) The enzyme "aldehyde oxidase" is an iminium oxidase: Reaction with nicotine iminium ion. Biochem Biophys Res Commun 91:991-996.
5. Coller BS (1990) Platelets in thrombolytic therapy. N Engl J Med 322:33-42.
6. EPIC Investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 330:956-961.
7. Frishman WH, Burns B, Atac B, Alturk N, Altajar B and Lerrick K (1995) Novel antiplatelet therapies for treatment of patients with ischemic heart disease: Inhibition of the platelet glycoprotein Iib/IIIa integrin receptor. Am Heart J 130:877-892.
8. Gibaldi M and Perrier D (1982) Pharmacokinetics, 2nd ed., Marcel Dekker, New York.
9. Hand EL, Gilben JD, Yuan AS, Olah TV and Hichens M (1994) Determination of MK-383, a non-peptide fibrinogen receptor antagonist, in human plasma and urine by radioimmunoassay J Pharm Biomed Anal 12:1047-1053.
10. Harrington RA, Schulman SP, Kleiman NS, Lincoff AM, Goldschmidt-Clermont PJ, Joseph D, Sigmon KN, Parker J, Marchant K and Kitt MM (1994) Profound sustained and reversible platelet inhibition following administration of a glycoprotein IIb/IIIa inhibitor with and without heparin in patients with unstable angina. Circulation 90:1-232.
11. Hartman GD, Egbertson MS, Halczenko, Laswell WL, Duggan ME, Smith RL, Naylor AM, Manno PD, Lynch RJ, Zhang G, Chang CT-C and Gould RJ (1992) Non-peptide fibrinogen receptor antagonists: 1. Discovery and design of exosite inhibitors. J Med Chem 35:4640-4642.
12. Kereiakes D, Kleiman N, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herman HC, Sutton J, Weaver WD, McKee D and Sax FL (1994) A dosing study in high-risk PTCA of MK-383, a platelet GP IIb/IIIa antagonist. Circulation 90:1-21.
13. Leung L and Nachman R (1986) Molecular mechanisms of platelet aggregation. Annu Rev Med 37:179-186.
14. Smyth SS, Joneckis CC and Parise LV (1993) Regulation of vascular integrins. Blood 81:2827-2843.
15. Muller TH, Weisenberger H, Brickl R, Kirchner M, Narjes H, Himmelsbach F, Guth B and Krause J (1995) Pharmaco-dynamics and -kinetics of BIBU 52, a platelet glycoprotein (GP) IIb/IIIa antagonist, and its orally active prodrug BIBU 104 in man. Thromb Haemost 73:1445.
16. 1′(5′) iminium ion: A newly discovered intermediate in the metabolism of nicotine. J Biol Chem 248:2796-2800.
17. Nakajima M, Yamamoto T, Nunoya K-I, Yokoi T, Nagashima K, Inoue I, Funae Y, Shimada N, Kamatak T and Kurowa Y (1996) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24:1212-1217
18. 1′(5′)-iminium ion to cotinine by rabbit liver microsomes. Biochem Pharmacol 39:R1-R4.
19. Ortiz de Montellano PR (1995) Oxygen activation and reactivity, in Cytochrome P450 (Ortiz de Montellano ed) pp 45-303, Plenum Press, New York.
20. Phillips DR, Charo IF, Parise LV and Fitzgerald LA (1988) The platelet membrane glycoprotein IIb/IIIa complex. Blood 71:831-843.
21. Samanen J, Ali F, Romoff T, Calvo R, Sorenson E, Vasko J, Storer B, Berry D, Bennett D, Strohsacker M, Powers D, Stadel J and Nichols A (1991) Development of a small RGD peptide fibrinogen receptor antagonist with potent anti-aggregatory activity in vitro. J Med Chem 34:3114-3125.
22. Theroux P, Kouz S, Knudtson ML, Kells C, Naismith J, Roy L, Dalle Ave S, Steiner B, Xiao Z and Rapold H (1994) A randomized double-blind controlled trial with the non-peptide platelet GP IIb/IIIa antagonist Ro 44-9883 in unstable angina. Circulation 90:1-242.
23. Topol EJ (1995) Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa inhibitors. Am Heart J 130:662-672.
24. Williams DE, Shigenaga MK and Castagnoli N (1990) The role of cytochrome P-450 and flavin-containing monooxygenase in the metabolism of (S)-nicotine by rabbit lung. Drug Metab Dispos 18:418-428.
25. Zablocki JA, Tjoeng FS, Bovy PR, Miyano M, Garland RB, Williams K, Schretzman L, Zuper ME, Rico JG, Lindmark RJ, Toth MV, McMackins DE, Adams SP, Panzer-Knodle SG, Nicholson NS, Taite BB, Salyers AK, King LW, Campion JG and Feigen LP (1995) A novel series of orally active antiplatelet agents. Bioorgan Med Chem 3:539-551.